ALCOR Scientific
Private Company
Total funding raised: $11M
Overview
ALCOR Scientific has established itself as a specialized leader in the in-vitro diagnostics (IVD) market by re-engineering the century-old Erythrocyte Sedimentation Rate (ESR) test. Its flagship iSED product line utilizes novel photometric rheology technology to deliver results in 20 seconds with walk-away automation, addressing key laboratory pain points like short sample stability and manual labor. The company has achieved significant commercial traction, with its instruments used in over 60 countries and having delivered over 180 million patient results, positioning it as a high-growth player in the lab efficiency segment. ALCOR operates as a private, revenue-generating company with a clear focus on expanding its global distributor network and product portfolio.
Technology Platform
Proprietary photometric rheology technology that measures red blood cell aggregation (rouleaux formation) to determine Erythrocyte Sedimentation Rate (ESR) in 20 seconds, replacing traditional gravity-based methods.
Funding History
4Opportunities
Risk Factors
Competitive Landscape
ALCOR competes in the automated ESR analyzer segment against other IVD manufacturers that offer alternatives to the manual Westergren method. Its primary competitive advantages are its 20-second result time, 7x longer sample stability, and full walk-away automation. It also competes indirectly, as ESR itself can be substituted by other inflammatory tests like CRP in some clinical protocols, though ESR offers unique diagnostic information.